Podcasts about global drug survey

This year's Global Drug Survey throws a spotlight on understanding illegal steroid use. So, what are the risks, what drives people to take them and how much does stigma prevent people getting the help they need.

Meet the Magic of Mushrooms on Colour BlindnessRoughly 300 million people have a colour vision deficiency. But with a few mushrooms and some magic, those who experience colourblindness might be able to see a whole range of colors for the first time.References:Magic Mushrooms seem to have a strange effect on color blindness | Science AlertIshihara test: Color Blind Test | ColormaxWhat is LSD | Science AlertCase report: Prolonged amelioration of mild red-green color vision deficiency following psilocybin mushroom use | Drug Science, Policy and LawImproved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017 | Drug Science, Policy and Law

In the midst of a battle with cancer, Kathy Kral found herself facing another diagnosis: major depression.So, Kathy signed up for a clinical study to see if psilocybin – the psychedelic compound found in “magic mushrooms” – could help her confront her fears about cancer and death, as well as her deepest inner demons.Featuring Kathleen Kral, Manish Agrawal, and Norma Stevens. SUPPORTOutside/In is made possible with listener support. Click here to become a sustaining member of Outside/In. Talk to us! Follow Outside/In on Instagram or Twitter, or discuss the show in our private listener group on Facebook. Submit a question to our Outside/Inbox. We answer queries about the natural world, climate change, sustainability, and human evolution. You can send a voice memo to outsidein@nhpr.org or leave a message on our hotline, 1-844-GO-OTTER (844-466-8837). LINKSCan Psychedelic Therapy Offer a Sense of Peace for the Dying?The Sunstone Psilocybin Playlist patients listen to during their psychedelic tripsCitationsIn the psilocybin study Kathy Kral participated in, 80% of participants experienced a significant reduction in depression, and half were no longer depressed at all. These results were persistent even a year and a half after their psilocybin sessions.Psychedelics cause hallucinations because they compromise the part of the brain that processes what you see, and promote communication between different parts of your brain that usually don't talk to each other.Risks associated with psilocybin range from nausea and increased heart rate, to Hallucination Persisting Perception Disorder where people continue having hallucinations for months or years after the trip has ended. But magic mushrooms had the lowest rates of associated emergency room visits out of any drug surveyed by the Global Drug Survey in 2019, 2020, and 2021. And researchers have found that psychedelics are not addictive in lab animals, and the lethal dose of psilocybin is so high that overdoses are impractical and rare.  CREDITSHost: Nate HegyiReported, produced, and mixed by Felix PoonEdited by Taylor Quimby with help from Rebecca Lavoie, Nate Hegyi, Justine Paradis, and Jeongyoon Han.Rebecca Lavoie is our Executive ProducerSpecial thanks to Evan Craig, Heather Honstein, Kathryn Tucker, and Erinn Baldeshwiler.Music for this episode by Blue Dot Sessions, Pawan Krishna, the Warsaw National Philharmonic Orchestra, and Paul De Bra.Theme music by Breakmaster Cylinder.Outside/In is a production of New Hampshire Public Radio.

Don't do drugs, kids.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This morning on Get Fact'd with Darren Maule he shares some of the most mind-blowing facts. - According to a 2016 study, ending texts with a certain punctuation mark makes things tense. - According to the 2021 Global Drug Survey, a certain nationality of people are the most likely to get drunk and then regret it. Could it be us? - Financially speaking, people value something quite specific about Christmas gifts. Take a listen to these.

Micro Dosing!See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

While Australians who participated in the Global Drug Survey drank on about the average number of days in 2020, the number of days they reported getting drunk was far above the international average. See omnystudio.com/listener for privacy information.

Thema dieser Folge ist: Drogenkonsum. Helena hat sich die Global Drug Survey angesehen und wir haben uns darüber Gedanken gemacht, was wir aus solchen Erhebungen zum Drogenkonsum ziehen können. Wir haben uns einige Aspekte dieser Befragung und der Auswertung angesehen. Natürlich kommen wir nicht drum rum über die legale Droge überhaupt zu reden: Alkohol. Im Weiteren wollen wir uns dann vor allem Drogen ansehen, die auch einen medizinischen Nutzen haben. Und am Ende haben wir noch ein paar Überlegungen zur Drogenpolitik. Inhaltshinweis: In dieser Folge geht es also um Drogen, aber psychische Erkrankungen wie Depressionen oder die Posttraumatische Belastungsstörung werden ebenfalls erwähnt.

Bulunduğumuz haftanın bilim dünyasından önemli gelişmeleri sizler için derledik. Discovery of terrestrial allabogdanite (Fe,Ni) 2P, and the effect of Ni and Mo substitution on the barringerite allabogdanite high pressure transition. https://doi.org/10.2138/am-2021-7621 Improved color blindness symptoms associated with recreational psychedelic use, results from the Global Drug Survey 2017. https://doi.org/10.1177/2050324520942345 Regeneration in starved planarians depends on TRiC/CCT subunits modulating the unfolded protein response. https://doi.org/10.15252/embr.202152905 CRISPR-CAS9 in vivo gene editing for transthyretin amyloidosis. https://doi.org/10.1056/nejmoa2107454 Bize 101.podcast.info@gmail.com adresinden ulaşabilirsiniz.

Julia Buxton is British Academy Global Professor. Her research focuses on illicit drug markets and the impact of counter narcotics policies on development, gender equality and security. In her career she's led projects and worked with multiple universities around the world including the Central European University in Budapest. Outside of Europe, she has geographical expertise on Latin America and is a specialist on Venezuela.  Now, back in England, she's working on The Global Drug Survey project, inquiring about the drug policy preferences of drug users themselves. With this innovative approach she's joining the conversation on drugs on the political scene in the UK.  Tune into this week's episode to find out about how drug policies that are older than the Internet, Thatcherism and HIV treatment contribute to inequalities arising between different countries and genders. Shownotes:OpioidsCannabisOpen Society FoundationsJonathan SorosUN Sustainable Development GoalsViktor OrbanPopulismSyrian refugee crisis in HungaryNativismThe Impact of Global Drug Policy on Women: Shifting the Needle - book by Julia Buxton Advisory Council on the Misuse of Drugs (ACMD)Ingrid WalkerJudith AldridgeDarknet“Do Darknet Drug Markets Make the Bad Guys Less Bad?” Aldridge Asks Keir StarmerNicola SturgeonHeroin CocaineGreenwich biosciences  ★ Support this podcast ★

Computational neuroscientist and biomedical software engineer Balázs Szigeti, PhD. is on the podcast this week to talk about the science behind the increasingly popular practice of microdosing. Microdosing is broadly defined as the regular use of low-dose psychedelic substances such as LSD or psilocybin mushrooms. Distinct from psychedelic therapy or common recreational use, microdosing involves using only around 10% of a typical dose of the drug. Balázs has collaborated with the Global Drug Survey to quantitatively study drug use patterns, and most recently he designed and led the Imperial College self-blinding microdose study published in the open-access journal eLife Sciences. On this podcast, Balázs discusses the results of his study that examined whether psychedelic microdosing can improve cognitive function and psychological well-being. He reviews the existing clinical research on the topic and describes the innovative study design that enabled him to run the largest placebo-controlled study on psychedelics to date. Balázs also reveals the surprising results of the study, which suggest that expectation may play a significant role in feeling better. Here’s the outline of this interview with Balázs Szigeti: [00:00:17] Imperial College London Centre for Psychedelic Research. [00:02:47] The current science on microdosing. [00:04:12] Paper: Szigeti, Balázs, et al. "Self-blinding citizen science to explore psychedelic microdosing." ELife 10 (2021): e62878.  [00:04:18] Citizen Science and self-blinding. [00:16:26] Results of the study. [00:21:39] Sourcing LSD and LSD analogues. [00:22:24] Book: American Kingpin, by Nick Bilton. [00:24:35] Existing clinical studies on microdosing: 1. Yanakieva, Steliana, et al. "The effects of microdose LSD on time perception: a randomised, double-blind, placebo-controlled trial." Psychopharmacology 236.4 (2019): 1159-1170; 2. Hutten, Nadia RPW, et al. "Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study." European Neuropsychopharmacology 41 (2020): 81-91; 3. Bershad, Anya K., et al. "Acute subjective and behavioral effects of microdoses of lysergic acid diethylamide in healthy human volunteers." Biological psychiatry 86.10 (2019): 792-800. [00:27:53] The key to a strong placebo response. [00:29:36] Acute and post-acute outcomes. [00:41:44] Book: Cure: A Journey into the Science of Mind Over Body by Jo Marchant. [00:44:01] Hamilton Depression Scale.  [00:52:13] Future directions and testing additional substances. [00:54:44] examine.com. [00:55:03] labdoor.com. [00:55:52] mydelica.com for Balazs’ self-blinding microdose study 2.0. [00:57:27] Limitations of the study. [01:07:27] Selfblinding-microdose.org.

In last week's Solidarity Fridays episode, Kyle, Joe, and Michelle talked a lot about a landmark new trial to study microdosing and the placebo effect. And this week (the big SF50!), they're joined by 2 key members of that very trial, lead researcher Balázs Szigeti and principal investigator David Erritzoe.  Szigeti and Erritzoe explain all the factors of the trial in great detail: how participants blinded themselves and the complications with capsule weight (and burping?), what substances participants took, how they were able to track which participants were in which group, what "breaking blind" meant specific to this trial, how they essentially used cognitive performance tests as a control, how depression factored in (or didn't), why they specifically chose people with experience in psychedelics, and why this study mimics real-life microdosing so perfectly. And they talk about the fascinating results: that while across the board, people scored better and felt better after microdosing for 4 weeks, the people who thought they were microdosing did too, and nearly as much.  They're working on future editions of the trial- one that will likely be much longer in duration and work through the new psychedelic app, Mydelica, and one that will be more traditionally placed in a lab, where they can study the neuroscience present (or maybe not so present) in microdosing. Notable Quotes “If you really simplify it, you can say that ...in a way, the guess was [a] 10 times better predictor of some of these acute outcomes than was the actual condition- what they actually took.” -David Erritzoe   “I’m not trying to invalidate your experience by saying, “This is placebo,” but I’m saying it could be, because that’s what the trial actually came up with. But it doesn’t mean that those experiences are not real, it’s just that a lot of those effects come from a combination of hoping, believing, expecting things to become better, and then your mind [does] magical tricks. And that’s the beauty of placebo, in particular when it comes to mental health and well-being.” -David Erritzoe “Based on our data, there is no question that people do better after microdosing. It is just that people feel equally better after they have taken a placebo.” -Balázs Szigeti “I was in a panel recently about microdosing where the people kept asking, ‘Oh, but what are the mechanisms?’ ‘How is it that microdosing works?’ And I’m like, ‘Let’s maybe start by seeing whether it works.’ It’s only so interesting to find out how something works if it works.” -David Erritzoe Links Selfblinding-microdose.org Elifesciences.org: Self-blinding citizen science to explore psychedelic microdosing Szigeti and Erritzoe’s last appearance on Psychedelics Today Mydelica.com About Balázs Szigeti, PhD Dr. Balazs Szigeti has studied theoretical physics at Imperial College, but turned towards neuroscience for his PhD studies at the University of Edinburgh. His main work is about the behavioural neuroscience of invertebrates, but he has a diverse scientific portfolio that includes computational neuroscience and driving forward the OpenWorm open science initiative. Balazs is also the editor of the Dose of Science blog that is published in collaboration with the Drugreporter website. Dose of Science discusses and critically assesses scientific studies about recreational drugs. Recently Balazs has started a collaboration with the Global Drug Survey to quantitatively compare the dose of recreational users of various drugs with the scientific literature. About David Erritzoe, PhD Dr. David Erritzoe is qualified as a medical doctor from Copenhagen University Medical School and currently holds an Academic Clinical Lectureship in Psychiatry at Imperial College London. Alongside his clinical training in medicine/psychiatry, David has been involved in psychopharmacological research, using brain-imaging techniques such as PET and MRI. He has conducted post-doc imaging research in the neurobiology of addictions and major depression. Together with Prof Nutt and Dr Carhart-Harris he is also investigating the neurobiology and therapeutic potential of MDMA and classic psychedelics. Support the show! Patreon Leave us a review on Facebook or iTunes Share us with your friends Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics  

Jack Revell from Drugswrap talks the week in drug news with us.Follow Drugswrap on TwitterDr. Monica Barratttwitter.com/monicabarratt(link is external)Dr. Monica Barratt is a social scientist, focusing on alcohol and other drug policy, especially around how drug markets operate in the online world. Monica works with the Drug Policy Modelling Program, part of Australia's National Drug and Alcohol Research Centre at the University of New South Wales and currently a senior research fellow with RMIT UniversityDr. Nicole Leetwitter.com/drnicolelee(link is external)Dr Nicole Lee is psychologist, with expertise in alcohol and other drug policy and practice. Nicole is an adjunct professor at the National Drug Research Institute at Curtin University, a member of the Australian National Advisory Council on Alcohol and Drugs and the Director of 360 Edge, a specialist alcohol and other drugs consultancy which helps bring research into policy and practice. Global Drug Survey COVID-19 EditionThe GDS Special Edition on COVID-19 was developed as part of a global effort to better understand the impact of the pandemic on people’s lives with a specific focus on the use of alcohol and other drugs, mental health and relationships. Over 55,000 people took part. The survey ran for 7 weeks in (May – June 2020)VIEW THE GLOBAL DRUG SURVEY RESULTS(link is external)National Drug Strategy Household Survey 2019 Australian Institute of Health and Welfare(link is external)

Jack Revell from Drugswrap talks the week in drug news with us.Follow Drugswrap on TwitterDr. Monica Barratttwitter.com/monicabarrattDr. Monica Barratt is a social scientist, focusing on alcohol and other drug policy, especially around how drug markets operate in the online world. Monica works with the Drug Policy Modelling Program, part of Australia's National Drug and Alcohol Research Centre at the University of New South Wales and currently a senior research fellow with RMIT UniversityDr. Nicole Leetwitter.com/drnicoleleeDr Nicole Lee is psychologist, with expertise in alcohol and other drug policy and practice. Nicole is an adjunct professor at the National Drug Research Institute at Curtin University, a member of the Australian National Advisory Council on Alcohol and Drugs and the Director of 360 Edge, a specialist alcohol and other drugs consultancy which helps bring research into policy and practice. Global Drug Survey COVID-19 EditionThe GDS Special Edition on COVID-19 was developed as part of a global effort to better understand the impact of the pandemic on people’s lives with a specific focus on the use of alcohol and other drugs, mental health and relationships. Over 55,000 people took part. The survey ran for 7 weeks in (May – June 2020)VIEW THE GLOBAL DRUG SURVEY RESULTSNational Drug Strategy Household Survey 2019 Australian Institute of Health and Welfare

Informatie uit High Tea aflevering 23, met Has Cornelissen Wat zit er in je joint vandaag? -Has: Polm van coffeeshop Nogal Wiedes, Amsterdam -Derrick: Sample HighLife Cup 2020 in de ‘Haze on soil' categorie (E19), waarschijnlijk Amnesia -Rens: OG Reek'n van Devil's Harvest Seeds Nog iets nieuws? -Aanmelding telers wietproef start op 1 juli: https://voc-nederland.org/blog/2020/06/09/telers-wietproef-kunnen-zich-vanaf-1-juli-melden-worden-bedolven-onder-documenten/ -Coronamaatregelen coffeeshops, reactie August de Loor: https://augustdeloor.nl/lock-down-logboek-drug-en-druggebruik-nr-7-rectificatie/ -Coffeeshops mogen vanaf 1 juli weer volledig open: https://voc-nederland.org/blog/2020/06/25/coffeeshops-mogen-vanaf-1-juli-weer-volledig-open/ -Duitse zorgverzekeraars vergoedden recordbedrag aan medicinale cannabis: https://mjbizdaily.com/insurance-covered-reimbursements-for-medical-cannabis-sets-record-in-germany/ -US Attorney General falsely targeted 10 cannabis companies, whistleblower says: https://www.leafly.com/news/politics/breaking-us-attorney-general-falsely-targeted-10-cannabis-companies-whistleblower-says Has Cornelissen https://www.legalize.net/ https://www.psychotropica.nl/ https://www.reguleren.com/ (De Regulator) Over Adam Windstock, de man achter de Global Drug Survey: https://www.vice.com/nl/article/3b7ewy/global-drugs-survey-2015-adam-windstock-308 De Ouwe Doos Podcast en documentaire over 50 jaar Holland Pop Festival: https://www.spreekbuis.nl/de-holland-pop-festival-podcast-50-jaar-liefde-vrijheid-en-muziek/ Wijze woorden “Het waarnemen van het kleine is het geheim van het helder zien, het beschermen van wat zacht en teer is, is het geheim van kracht.” Lao Tse, Chinese filosoof Sponsor Aflevering 23 van High Tea met Derrick & Rens is mede mogelijk gemaakt door Super Sativa Seed Club, hoogwaardige cannabiszaden voor geavanceerde kwekers verkrijgbaar op www.supersativaseedclub.com. Tune Website Mooon, de makers van onze begin- en eindtune ‘Mary You Wanna': http://www.mooonband.com/ Reacties van luisteraars Elke aflevering belonen we de leukste luisteraarsreactie met een groene prijs. Mail naar info@highteapotcast.nl of reageer in de comments. Volg High Tea ook op Instagram: @Highteapotcast

Der EU-Chefverhandler Michel Barnier wirkte genervt. Heute ist die vorerst letzte Verhandlungsrunde über die künftigen Beziehungen zwischen der EU und dem Vereinigten Königreich zu Ende gegangen – mal wieder ohne nennenswerte Fortschritte. Besonders umstritten ist der Zugang europäischer Fischerinnen und Fischer zu den britischen Fanggründen. Die EU wirft den Briten vor, ihre Zusagen aus dem Austrittsabkommen vom Oktober nicht einhalten zu wollen, während Boris Johnsons Verhandlungsführer von einer positiven Gesprächsatmosphäre berichten. Weitere Themen: Die EU-Binnengrenzen öffnen bis spätestens Ende Juni und der Bundesrat beschließt ein weitgehendes Verbot sogenannter "Konversionstherapien" für Homosexuelle. Außerdem berichtet die Wissenschaftsjournalistin Linda Fischer über die vorläufigen Ergebnisse des Global Drug Survey und über den Alkoholkonsum der Deutschen in Corona-Zeiten. Hier können Sie am Global Drug Survey teilnehmen: https://www.globaldrugsurvey.world/s3/COVID19-LANGUAGE-SELECTION Moderation: Ole Pflüger Redaktion: Pia Rauschenberger Sie erreichen uns per Mail an wasjetzt@zeit.de.

Adam Winstock joins Professor David Nutt to discuss how drug use has changed in the past 20 years and the data that he has collected as a part of the Global Drug Survey (GDS).Using anonymous online research methods Global Drug Survey runs an annual survey collecting information on people's drug use. Using this data, the Global Drug Survey creates digital health applications delivering screening and brief interventions for drugs. Survey findings are frank, honest, and revealing. GDS explores the positives and negatives of drug use and detects new drugs trends as soon as they appear. GDS has a unique insight into personal decision-making about drug use. Their international networks of researchers and specialists have extensive experience in data analysis and report writing.Professor Winstock is a Consultant Addiction Psychiatrist based in London where is he looks after the care of people who use drugs in prison. He is also an honorary clinical professor at University College London, he was previously Consultant Psychiatrist at the Maudsley Hospital and Senior Lecturer at the Institute of Psychiatry, Kings College London. Adam has published over 100 research papers and has developed particular clinical and research expertise in the areas of cannabis, new drugs and chemsex. He is also founder and director of Global Drug Survey, the world's biggest annual survey of drug use trends, the architect of online and smart phone apps drugs meter and Drinks Meter, and the ultra-brief feedback and assessment tool for cannabis use.Mixmag - https://mixmag.net/GDS Corona - https://www.globaldrugsurvey.com/covid19/GHB / GBL - https://drugscience.org.uk/drug-information/ghb-gbl/GDS highway code - https://www.globaldrugsurvey.com/brand/the-highway-code/Become a Drug Science Community Member: https://www.donate.drugscience.org.uk/Twitter: @ProfDavidNutt @Drug_ScienceA Fascinate Productions podcast for Drug Science ★ Support this podcast ★

Guest : Dr Keith Scott | Co-Founder at South African Drug Policy Initiative (SADPI)| The World’s largest independent survey of drug use (Global Drug Survey Special Edition on COVID-19) has just gone live at https://www.globaldrugsurvey.com and will discover what impact lockdown is having on our recreational habits. This year’s survey, which opened this week, is seeking to track changes in alcohol and drug use during Covid-19 by asking participants how their consumption has changed as a result of the pandemic. The survey includes a number of opt-in questions about tensions in relationships before and after Covid-19, and about behaviours ranging from physical abuse to being stopped from seeing or talking to family or friends, having access to money or checking contacts on social media. Conducted in sixteen different languages, the GDS is the biggest survey of its kind in the world with over 130,000 people confidentially submitting data last year.

Suzi Gage interviews Adam Winstock about the Global Drug SurveyGlobal Drug Survey's website is here: https://www.globaldrugsurvey.com/ See acast.com/privacy for privacy and opt-out information.

Download In this episode, hosts Kyle and Joe interview Balázs Szigeti, PhD and David Erritzoe, PhD to discuss the self-blinded microdosing study in collaboration with the Imperial College London. In this episode, they explore the self-blinding study and it’s pros and limitations, with the aim to collect data on microdosing and its possible benefits. 3 Key Points: Microdosing (LSD) has the least amount of research so far among research on drugs like Psilocybin, MDMA and Ketamine. This microdosing study includes a procedure on how self experimenters can implement placebo control. This will help determine whether microdosers feel benefits due to the placebo effect or because of the pharmacological action of the microdose. Just because microdosing may have a placebo effect (the way a user feels while taking it) it may actually have benefits that one cannot necessarily ‘feel’ (users may become more creative, have better problem solving skills, etc). Support the show Patreon Leave us a review on iTunes Share us with your friends – favorite podcast, etc Join our Facebook group - Psychedelics Today group – Find the others and create community. Navigating Psychedelics Show Notes About Balázs Balazs attended his undergrad in the UK at Imperial College and studied Theoretical Physics He moved to Scotland to get his PhD in Computational Neuroscience He became interested in psychedelics via the Global Drug Survey He was doing MDMA research and then the microdosing project came to him About David He is a medical doctor and works in clinical psychology doing research He does brain imaging and his background has been in addiction, depression and schizophrenia He did his postdoc at Imperial and worked with Robert Carhart Harris He worked in a clinical trial working with people of treatment resistant depression He is currently working on an online survey for microdosing Psychedelic Medicine MDMA for PTSD is the most advanced in terms of available scientific evidence for psychedelic medicine There is already a big gap in psilocybin vs MDMA for treatment There isn't much research on microdosing yet In order to do research on microdosing, you'd have to bring in a ‘patient’ and have them in the lab for many hours at a time, very frequently, and it's not practical The Microdosing Study In this microdosing study, they are testing cognitive function The user will have to fill out a questionnaire throughout the duration of the microdose There were a lot of things, very political for the downfall of psychedelic science When the double-blind method was introduced for science, it used methods that would have compromised the ‘setting’ of taking psychedelics There is a manual that the users have to follow for the setup process Its a semi-randomized process where they take the microdose over 4 weeks and it may be either the psychedelic or a placebo It works on a method of a dose hidden in a capsule assigned to a QR code, where the user doesn't know what they take until the end of the study This is a study inviting people that plan to microdose a blotter based psychedelic Its a hands-off study of observation, based on a users own plan on taking the substance Limitations of the Study Its half-way between a clinical study and an observational study They aren't sending the users the LSD, they are just providing the platform for the users to share their experience on In this trial, the flaw is that the research team doesn't know the dose size of the blotter the user takes, it could start as a 100mg, more, less. Its a variable that cannot be controlled The fix would be to have the LSD sent to the lab, tested for dose size, and then sent back to the user (anonymously), but since it's illegal it cannot be done It's also hard to determine even distribution of a blotter into microdose size They don't know if the user is cutting the blotter paper like a pie or in squares Also, because the drug is being bought on the black market, they wont know if there are adulterants in the drug unless the user tests the drug themselves David and Balázs also say that based on current findings, most LSD tested is pure LSD, where a drug like MDMA is more common to contain an adulterant They do have plans to extend the study to include plant based psychedelics and volumetric dosing What is a Psychedelic Microdose? Psychedelic microdosing is not the same as Pharmacological microdosing A microdose in pharmacological context is 1/100th of a dose, where a psychedelic microdose is more like 1/10th of a dose Is Microdosing Worth it? People like David Nichols and Ben Sessa think microdosing is pointless It could be that microdosing is a glorified placebo effect Most people who are microdosing have had previous experience with psychedelics People are doing it because they believe there is a benefit that comes from it The placebo control is the most important component of this self-blinded method People say that microdosing stimulates their creativity, but creativity is hard to measure One thing they could measure is personality through a personality assessment One thing that has been studied is an increase in the ‘Openness’ personality trait after psychedelic use The flaw is that a personality test is a person answering questions about themselves Current Findings The benefit of this study, is it doesn't take people out of their natural, personal setting Based on the feedback already received, the users are getting their guess right only half of the time, on whether it is the microdose or the placebo Just because microdosing may have a placebo effect (the way they feel while taking it) it may actually have benefits (users may be more creative, have better problem solving skills, etc). Homeopathy is widely believed to be a placebo effect in the scientific community, but the homeopathy is continuing to grow Links Self-blinding Microdose Study About Balázs Szigeti, PhD Dr. Balazs Szigeti has studied theoretical physics at Imperial College, but turned towards neuroscience for his PhD studies at the University of Edinburgh. His main work is about the behavioural neuroscience of invertebrates, but he has a diverse scientific portfolio that includes computational neuroscience and driving forward the OpenWorm open science initiative. Balazs is also the editor of the Dose of Science blog that is published in collaboration with the Drugreporter website. Dose of Science discusses and critically assesses scientific studies about recreational drugs. Recently Balazs has started a collaboration with the Global Drug Survey to quantitatively compare the dose of recreational users of various drugs with the scientific literature. About David Erritzoe, PhD Dr. David Erritzoe is qualified as a medical doctor from Copenhagen University Medical School and currently holds an Academic Clinical Lectureship in Psychiatry at Imperial College London. Alongside his clinical training in medicine/psychiatry, David has been involved in psychopharmacological research, using brain-imaging techniques such as PET and MRI. He has conducted post-doc imaging research in the neurobiology of addictions and major depression. Together with Prof Nutt and Dr Carhart-Harris he is also investigating the neurobiology and therapeutic potential of MDMA and classic psychedelics.

Interview location: SkypeInterview date: Tue 23rd July 2018Campaign: Free RossI first met Lyn Ulbricht in Austin in March earlier this year to discuss the case of her son, Ross Ulbricht, the founder of the online marketplace: The Silk Road. Our interview was before the decision of the Supreme Court to decline their petition to have the case reviewed.Ross and the family are now left with very few options and are focused on raising awareness in political circles in search of clemency from the President.If you are interested in the case and did not hear my first interview with Lyn, I would recommend listening to it or watching the interview on YouTube.The petition to the Supreme Court focused on alleged violations of both the 4th and 6th amendments, yet the Supreme Court denied Ross a retrial and provided no comment. The case is widely misunderstood, often with those not aware of the full facts of the case raising the charge of murder for hire as justification for the sentence, a charge which has been dropped.Ross is facing the rest of his life in prison for what was a non-violent crime, and for which the Drug Policy Alliance said:In a world operating on the modus operandi of prohibition, users are often left in the dark and all sorts of other precarious situations; purchasing at music festivals is one glaring example. “The overwhelming consensus among users of the Silk Road,” Bartlett realized, “was that the quality of the product was far higher and its purity far more reliable than anything you’d find on a street corner.” Goodbye stranger-danger, dark alleyways, and unknown/unlabeled substances. The Global Drug Survey of 2015 confirmed this, stating “reduced rates of exposure to violence, less adulterated drugs, more confidence in product quality and removal from street dealing were clear benefits.” Will this access lead some to experimenting with other drugs? Sure, maybe. What’s clear however, is within this system, people are able to better regulate and reduce harm associated with their drug use.In this interview, I talk to Lyn about the denial of the Supreme Court, the support of the Libertarian Party, the petition for clemency and life for Ross inside the prison.-----If you enjoy The What Bitcoin Did Podcast you can help support the show my doing the following:Become a Patron and get access to shows early or help contributeMake a tip:Bitcoin: 3FiC6w7eb3dkcaNHMAnj39ANTAkv8Ufi2SQR Codes: Bitcoin | Ethereum | Litecoin | Monero | ZCash | RipplecoinIf you do send a tip then please email me so that I can say thank youSubscribe on iTunes | Spotify | Stitcher | SoundCloud | YouTube | TuneIn | RSS FeedLeave a review on iTunesShare the show and episodes with your friends and familySubscribe to the newsletter on my websiteFollow me on Twitter Personal | Twitter Podcast | Instagram | Medium | YouTubeIf you are interested in sponsoring the show, you can read more about that here or please feel free to drop me an email to discuss options.

Konkrete oder drohende Gefahr: Wann darf Bayerns Polizei nach dem neuen Gesetz jemanden überwachen? Außerdem im Nachrichtenpodcast: welche Drogen unsere Leser nehmen. In Bayern haben am Donnerstag mehr als 30.000 Menschen gegen das geplante Polizeiaufgabengesetz protestiert. Der bayerische Innenminister Joachim Hermann von der CSU sprach danach von "unbedarften Menschen", die auf "Lügenpropaganda" hereingefallen seien. Kritiker des Gesetzes warnen vor dem im Gesetzestext verankerten Begriff der "drohenden Gefahr". Die Polizei könne so Personen durchsuchen, abhören oder ihre Daten auslesen, ohne dass ein konkreter Verdacht auf eine Straftat besteht. Die CSU hält weiter an dem Gesetz fest, jetzt soll es der Landtag beschließen. Über das bayerische Polizeiaufgabengesetz sprechen wir mit Ferdinand Otto, Politikredakteur bei ZEIT ONLINE. Wann haben Sie zuletzt Drogen genommen? Und was zählen Sie eigentlich dazu? Ein Feierabendbier, ein paar Züge an einer Shisha? Ein Joint oder MDMA auf der Party am Wochenende? Und ab wann ist das gefährlich? 50.000 ZEIT-ONLINE-Leserinnen und -Leser haben auf die Frage geantwortet, welche Drogen sie nehmen, wie oft und wie viel sie diese konsumieren. ZEIT ONLINE arbeitet seit fünf Jahren mit dem Global Drug Survey zusammen, der weltweit größten Drogenumfrage im Netz. Über die Ergebnisse der neuesten Umfrage informiert Sven Stockrahm, der stellvertretende Leiter der Ressortgruppe Wissen und Digital bei ZEIT ONLINE. Außerdem erfahren Sie im Podcast, was es mit Hörtests für Pinguine auf sich hat.

Broadcast live from the Entheogenesis Australis (EGA) 2017 Psychedelic Symposium at Holmesglen in Eildon.Hosted by Nick WallisWith blanket bans on psychoactives increasing, cognitive liberty is in chains. Where does reform for laws covering psychedelics fit within drug law reform? In an environment where evidence is not the drive for policy how do we keep policy makers accountable? What have we learned recent work and development? How can you help with the next steps? A number of individuals who have been involved with drug law and policy activism will join a panel to discuss strategies for reform.The panel will bring along some recent examples of activism and workshop these with the audience, drawing out successful strategies, unsuccessful strategies and discussing potential future campaigns.PANELRICK DOBLINIn the mid 1970s MDMA, then known as Adam was used quietly in psychotherapy. In the 1980s, growing recreational use of Ecstasy led to the criminalization of the drug and the formation of MAPS in 1986. Now, MAPS is about to embark on FDA-approved Phase 3 research to make MDMA-assisted psychotherapy a legal treatment for PTSD. This talk will discuss the historical implications of MDMA use and the plans for ongoing clinical research.Rick Doblin, Ph.D., is the founder and executive director of the Multidisciplinary Association for Psychedelic Studies (MAPS). He received his doctorate in Public Policy from Harvard's Kennedy School of Government, where he wrote his dissertation on the regulation of the medical uses of psychedelics and marijuana and his Master's thesis on a survey of oncologists about smoked marijuana vs. the oral THC pill in nausea control for cancer patients. His undergraduate thesis at New College of Florida was a 25-year follow-up to the classic Good Friday Experiment, which evaluated the potential of psychedelic drugs to catalyze religious experiences. He also conducted a thirty-four year follow-up study to Timothy Leary's Concord Prison Experiment. Rick studied with Dr. Stanislav Grof and was among the first to be certified as a Holotropic Breathwork practitioner. His professional goal is to help develop legal contexts for the beneficial uses of psychedelics and marijuana, primarily as prescription medicines but also for personal growth for otherwise healthy people, and eventually to become a legally licensed psychedelic therapist. He founded MAPS in 1986, and currently resides in Boston with his wife and one of three children (two in college).MONICA BARRATTDR MONICA BARRATT is a social scientist at the Drug Policy Modelling Program, part of Australia's National Drug and Alcohol Research Centre at the University of New South Wales. Monica's work examines the social and public health implications of digital technologies for people who use illicit and emerging psychoactive drugs. Research topics emerging from this interest include online drug markets or cryptomarkets and policy responses to novel psychoactive substance evolution. She specialises in engaging hard-to-reach networks and groups in digital spaces in conversations about research and policy, to inform policy change. Monica also serves as an Editor for policy-related articles at the International Journal of Drug Policy, and as the Director of Research at the international drug harm reduction community Bluelight.org. Monica is a lead researcher for the Global Drug Survey. She is also a regular attendee and contributor to EGA, from the mid-2000s.NICK KENTNICK KENT works as a secondary school teacher in the areas of languages and the humanities. He is currently completing his Masters through research at the Melbourne Graduate School of Education, where he is undertaking a critical discourse analysis of school policies and resources as they relate to drug education, comparing both local and international examples. After completing the Grad. Dip in Teaching in 2015, Nick was perplexed at the lack of teacher training around student drug use and the silence of the education system on this issue, as well as the slow pace of drug reform more broadly. Inspired to learn more, and to advocate and research this area further, Nick helped found Students for Sensible Drug Policy Australia in 2016, setting up their second chapter at the University of Melbourne. Nick was instrumental in the UniMelb chapter's work in setting up a harm reduction program that would supply re-agent drug checking kits to students free of charge through the Student Union, and has travelled to numerous international conferences to represent this globally significant program. Nick draws upon his experience in nightclub and festival communities, as well as his experience volunteering with DanceWize as a Peer Educator and his policy and international experience with SSDP in both his teaching and his research.FIONA MEASHAMFiona Measham is co-founder & co-Director of ‘The Loop’. The Loop conducts forensic testing of drugs at UK festivals and nightclubs and provides associated welfare support. Fiona Measham was appointed Professor of Criminology in the School of Applied Social Sciences at Durham University in 2012. Fiona has conducted research for over two decades across a broad area of criminology and social policy, exploring changing trends in legal and illegal drugs; the night time economy and the socio-cultural context to consumption; gender; the regulation and policing of intoxication; electronic music scenes and club cultures; issues of deterrence, displacement and desistance; and broader policy implications. A key feature of her research has been the development of in-situmethods of data collection in pubs, clubs and festivals, a working environment with which she is familiar, having spent her early adulthood working in bars and clubs across several continents in various guises.BEN SESSADR BEN SESSA (MBBS BSc MRCPsych) is a consultant child and adolescent psychiatrist working in adult addiction services and with custodial detained young people in a secure adolescent setting. He trained at UCL medical school, graduating in 1997. He is interested in the developmental trajectory from child maltreatment to adult mental health disorders. Dr Sessa is currently a senior research fellow at Bristol, Cardiff and Imperial College London Universities, where he is conducting the UK's first clinical studies with MDMA-assisted therapy for the treatment of PTSD and alcohol dependence syndrome. In the last ten years he has worked on several UK-based human pharmacology trials as study doctor or as a healthy subject administering and receiving test doses of LSD, psilocybin, MDMA and ketamine. He is the author of several dozen peer-reviewed articles in the mainstream medical press and has written two books exploring psychedelic medicine; The Psychedelic Renaissance (2012) and To Fathom Hell or Soar Angelic (2015). In speaking publicly at universities and medical conferences, Dr Sessa is outspoken on lobbying for change in the current system by which drugs are classified in the UK, believing a more progressive policy of regulation would reduce the harms of recreational drug use and provide increased opportunities for clinical psychedelic research. He is a co-founder and director of the UK's Breaking Convention conference.

Sarah and Sam cover the week’s biggest stories in drugs and drug policy! News Updates: Marijuana Won Tuesday’s Election ‘Angry and ashamed,’ Overdose Prevention Ottawa packing up its tent House Republicans sustain LePage’s veto of bipartisan marijuana legislation Global Drug Survey 2018 Headlines: ETF Managers Group is turning its existing Tierra XP Latin America Real […] The post News: Marijuana Wins and the Global Drug Survey [#121] appeared first on This Week in Drugs.

Hjärtligt välkomna till säsong två avsnitt ett! I det här avsnittet pratar vi, mest Liam faktiskt, bl.a om att bruka cannabis. Nyheterna: Polen röstar ja för medicinsk cannabis http://volteface.me/poland-votes-legalise-medical-cannabis/  Nevadas lagliga försäljning börjar https://www.sydsvenskan.se/2017-07-01/gront-ljus-for-gras-gav-jubel-i-vegas  Danmark vill legalisera odling https://www.sydsvenskan.se/2017-06-30/cannabisodling-pa-vag-att-bli-lagligt-i-danmark-for-att-skapa-nya-jobb  Svensk kändis dömd för ringa narkotikabrott http://www.expressen.se/noje/kand-svensk-artist-doms-for-ringa-narkotikabrott-/  Nyheten om Global Drug Survey som DN tog bort https://www.theguardian.com/society/2017/may/23/study-hallucinogenic-mushrooms-safest-recreational-drug-lsd  Löven vill ha hårdare tag mot knarkare https://www.dn.se/nyheter/politik/regeringen-vill-infora-utbildningsplikt-for-nyanlanda/   Gilla gärna Facebooksidan och gå med i Normaliseringspoddens eftersnacksgrupp. Vi har precis som alla andra en Patreon för ekonomiska bidrag. Övrig socialmedia: En bra ursäkt att träffas @normaliserngspodden Sebastians Instagram @softdady Liams Twitter @mollebongen Kontakt: enbraursakt@gmail.com Tack för att du lyssnar. -Sebastian Svahn